Dr. Dominik Escher is a founding partner of Pureos Bioventures and a co-founder and Executive Chairman of CDR-Life. Previously, he founded and served as CEO of ESBATech, which was acquired by Alcon (Novartis) for USD 589 million in 2009. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products, including Brolucizumab. From 2013 to 2022, he served as President of the Swiss Biotech Association, where he had been a Board Member since 2002. Dominik obtained his PhD in Molecular Biology from the University of Zurich.
BioTech
๐ Based in Zurich
Direct Professional Email Pattern
AI Outreach Agent Pitch Writer
Compose an personalized, high-converting outreach message targeting their exact investment interest...